Filed - Glenmark

More documents

Recommendations

Info

USA – Generic Formulations Current Status Rapidly built up a generic sales front end in the USA with investments in distribution, finance systems and sales team Organic and inorganic build-up of portfolio • Filed 10 ANDAs with US FDA towards FY07 filings (including partner filings and 2 Derma products and 2 FTFs) till Oct 06. In all, Glenmark has 25 ANDAs undergoing the US FDA approval process / launch. • 10 Generics on market – own and partnered • Focus on niche segment of controlled substances and dermatology 6 controlled substances licensed: 2 on market and 1 to be launched in November Paul Cap partnerships to finance product development in dermatology • Strategic co-development tie-ups concluded with Shasun and InvaGen: Together accounting for 20 additional filings to which Glenmark has marketing access Excellent sales performance – locked in excess of 20-25% of the US market on most products within first year of launch Achieved operating cash break-even in Q4 FY06 – within 3 years of set-up 15
USA – Generic Formulations Going forward: Multi-pronged build-out of Product Portfolio Own Filings: File 15-20 ANDAs in FY07; Includes 3-5 XRs, 6 Derma products and healthy & exciting mix of P-II, P-III & at least 3 FTF/P-IV opportunities Niche topical generics: working on 20+ steroidal, non-steroidal and combination topicals Niche controlled substances: Launched 2 controlled substances out of 5 products licensed from two US based firms; remaining to be launched by Feb 07. Segment offers lower competitive pressures. Further licensing efforts ongoing. Partnerships: Already announced partnerships (Shasun and InvaGen) will file over 8 generics with the US FDA in FY07. Current status Target for FY 2007 Marketed 10 Under Approval 25 Total Filings 35 Own filings 21 Marketed 18-22 Under approval 38-40 Total Filings 56-62 Own filings 15-20 Expect to Exceed April Guidance for FY07 16
Page 2 and 3: Disclaimer This presentation has be
Page 4 and 5: Background History 29-year old com
Page 6 and 7: Strategic roadmap: Transform into a
Page 8 and 9: Research and Development 5
Page 10 and 11: Licensing Strategy Partner Selectio
Page 12 and 13: NCE Pipeline Lead Target Indication
Page 14 and 15: NCE Pipeline Lead Target Indication
Page 16 and 17: Generic Formulations 13
Page 20 and 21: Europe - Start-up phase Strategy &
Page 22 and 23: Latin America Going forward Exp
Page 24 and 25: India Formulations Current Status
Page 26 and 27: India Formulations Moving forward,
Page 28 and 29: Active Pharmaceutical Ingredients C
Page 30 and 31: Financials and Projections Performa
Page 32 and 33: Financials and Projections Mileston
Page 34 and 35: Summary 31
Page 36: Thank you 33

Filed - Glenmark

Create successful ePaper yourself

Delete template?

Save as template?